scholarly journals Prevalence of Aspirin and Clopidogrel Resistance in Patients with Recurrent Ischaemic Cerebrovascular Disease

2021 ◽  
Vol 16 ◽  
Author(s):  
Niyata Hananta Karunawan ◽  
Rizaldy Taslim Pinzon
Keyword(s):  
Cerebrovascular Disease ◽  
Clopidogrel Resistance ◽  
Ischaemic Cerebrovascular Disease

Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily

2006 ◽  
Vol 96 (08) ◽  
pp. 154-159 ◽  
Author(s):  
Rosa-Maria Guéant-Rodriguez ◽  
Guido Anello ◽  
Rosario Spada ◽  
Antonino Romano ◽  
Adrian Fajardo ◽  
...  
Keyword(s):  
Cerebrovascular Disease ◽  
Vitamin B12 ◽  
Methylenetetrahydrofolate Reductase ◽  
Methionine Synthase ◽  
Italian Population ◽  
Significant Independent Predictor ◽  
Methionine Synthase Reductase ◽  
Ischaemic Cerebrovascular Disease ◽  
Folate And Vitamin B12 ◽  
Neutral Effect

SummaryAssociation between methylenetetrahydrofolate reductase polymorphism (MTHFR 677 C>T), a determinant of homocysteine plasma level (t-Hcys), with ischaemc cerebrovascular disease (iCVD) seems to be neutral in North Europe and North America. The association of 2756 A>G of methionine synthase (MTR), 66 A>G of methionine synthase reductase (MTRR) and 776 C>G of transcobalamin (TCN2) needs to be evaluated further. It was the objective of this study to evaluate the association of these polymorphisms, t-Hcys, vitamin B12 and folate levels with iCVD, in an Italian population from Sicily. We investigated the association of these polymorphisms, t-Hcys, vitamin B12 and folate with iCVD in 252 subjects, including 131 cases and 121 sexand agematched healthy controls. t-Hcys was higher in the iCVD group than in controls [15.3 (11.5–17.9) vs. 11.6 (9.4–14.5) µM; P=0. 0007] and also in subjects withTCN2 776CG genotype, compared to homozygous genotypes [13.5 (9.9± 16.9) vs. 11.7 (9.6 ± 14.4) µM; P=0. 0327]. The folate level in cases and controls was consistent with an adequate dietary intake [12.7 (9.0–15.3) vs. 12.5 (9.6–16.9) nM; P=0. 7203]. In multivariate analysis, t-Hcys was a significant independent predictor of iCVD with an odds ratio of 1.14 (95% C.I. : 1.06–1.24; P=0. 0006). No association was found between MTHFR, MTR, MTRR and TCN2 polymorphisms and iCVD risk. We have found an influence of t-Hcys and a neutral effect of MTHFR, MTR, MTRR and TCN2 on iCVD risk in Sicily. The neutral influence of these polymorphisms may be explained by adequate status in folate and vitamin B12. Other factors underlying the increased t-Hcys need further investigations.

Circulatory Reflexes in Cerebral Ischaemia Involving Different Vascular Territories

1970 ◽  
Vol 38 (4) ◽  
pp. 491-502 ◽  
Author(s):  
M. Gross
Keyword(s):  
Statistical Analysis ◽  
Arterial Pressure ◽  
Cerebrovascular Disease ◽  
Internal Carotid ◽  
Transient Ischaemic Attacks ◽  
Vasoconstrictor Response ◽  
Ischaemic Cerebrovascular Disease ◽  
Significant Difference ◽  
Valsalva's Manoeuvre ◽  
Circulatory Reflexes

1. Circulatory reflex function was assessed in a series of subjects with chronic ischaemic cerebrovascular disease and compared with a group of subjects with no known cerebrovascular disease by intra-arterial pressure responses to Valsalva's manoeuvre. 2. Circulatory reflexes were impaired in the patients with cerebrovascular disease as compared with controls, but statistical analysis indicated that age was a more important factor than chronic cerebrovascular disease in producing the deterioration. 3. No significant difference was found in the circulatory reflex function of subjects with ischaemia in the internal carotid territory when compared with those having ischaemia in the vertebrobasilar territory. 4. Combined ischaemia in both carotid and vertebrobasilar territories significantly impaired the cardioaccelerator but not the vasoconstrictor response to Valsalva's manoeuvre. 5. No significant difference was found in circulatory reflex function in subjects who had suffered cerebral infarction as opposed to transient ischaemic attacks.

Effects of Bezafibrate on Low HDL-Cholesterol in Patients with Ischaemic Cerebrovascular Disease: A Pilot Study

1981 ◽  
Vol 9 (5) ◽  
pp. 319-323 ◽  
Author(s):  
L Noring ◽  
K G Kjellin ◽  
H Ledermann
Keyword(s):  
Heart Disease ◽  
Pilot Study ◽  
Cerebrovascular Disease ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Ischaemic Cerebrovascular Disease ◽  
Low Hdl ◽  
Preliminary Study ◽  
Lipid Lowering Agent

Bezafibrate is a new lipid-lowering agent that quite consistently increases low HDL-cholesterol values in hyperlipoproteinaemic patients. The possible role of HDL-cholesterol as an anti-atherogenic factor has been frequently discussed, mainly in patients with ischaemic heart disease but recently also in ischaemic cerebrovascular disease (ICD). This is the first pilot study in six selected patients suffering from ICD who had at the same time low HDL-cholesterol values (< = 1.1 mmol/l) with otherwise normal lipids. After a wash-out period of 2 months duration these patients were treated with 200 mg bezafibrate t.i.d. for 2 months. They were then followed up for another 8 months. Bezafibrate therapy increased HDL-cholesterol (range 45–130%). Eight months after cessation of therapy five patients have returned to pathologically low HDL-levels and the sixth patient also has a relatively low value of 1.2 mmol/l. This small preliminary study cannot, however, provide evidence about the possible beneficial role of increasing HDL-cholesterol in patients with ICD. Further investigations are therefore in progress.

Role of Factor Xiii Val 34 Leu Polymorphism in Patients with Migraine

Cephalalgia ◽  
2001 ◽  
Vol 21 (8) ◽  
pp. 837-841 ◽  
Author(s):  
JA Iniesta ◽  
J Corral ◽  
R González-Conejero ◽  
A Díaz Ortuño ◽  
ML Martínez Navarro ◽  
...  
Keyword(s):  
Cerebrovascular Disease ◽  
Factor Xiii ◽  
Pcr Amplification ◽  
Protective Role ◽  
Ischaemic Cerebrovascular Disease ◽  
Allele Specific ◽  
Specific Restriction ◽  
A Chain ◽  
And Control

At present, it is contradictory to determine if the combination of certain prothrombotic polymorphisms and migraine increases the risk to develop ischaemic cerebrovascular disease. Recently, the common Val34Leu polymorphism of the A-chain factor XIII gene, associated with variations in factor XIII activity, has been suggested to play a significant role in the development of arterial and venous thrombotic disorders. We analysed the prevalence of this polymorphism in 17 patients with coexisting ischaemic cerebrovascular disease and migraine (5 with aura, and 12 without aura), 89 patients with migraine (43 with aura, and 46 without aura), 116 patients with ischaemic cerebrovascular disease, and 467 healthy Caucasian controls from the South of Spain. Genomic PCR amplification, using a mutated oligonucleotide, and allele-specific restriction assays were used for genotyping. The factor XIII Leu 34 variant was present in 47.1; 40.5; 34.9; and 35.1% of patients with coexisting ischaemic cerebrovascular disease and migraine, ischaemic cerebrovascular disease, migraine, and control subjects, respectively. These data suggest that the factor XIII Leu 34 allele does not play a protective role against these disorders in our population.

Sign in / Sign up

Export Citation Format

Share Document